AKT1 and breast cancer: Chen et al. (2024) reported that carvacrol (0, 100, 150, and 200 μM) inhibited cell development and induced apoptosis in Doxorubicin (Dox) resistant MDA‐MB‐231 breast cancer cells via cell cycle arrest at S and G2/M phases, enhanced Bax expression, while reduced Bcl‐2, PI3K, and P‐AKT expression.